ADAP - Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

2024-04-26 11:00:11 ET

Summary

• Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects.
• Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel, targeting soft tissue sarcoma.
• Adaptimmune Therapeutics has a reasonable financial position with $144 million in cash, but the termination of a collaboration deal with Genentech poses a risk. Expenses will be an issue soon.

Before we begin, I just want to remind you that I have prepared an article on ASCO and the various biotechnology companies that are showing up, you can read that here. There are over 50 companies being represented in the oral sessions, so click here to read more on what is going to be featured!...

For further details see: